Joe Tippens defied a terminal cancer diagnosis with a surprising, off-label treatment—and now doctors and patients around the world are taking notice.
Key Facts:
- Joe Tippens, diagnosed with terminal small cell lung cancer in 2016, credits the animal dewormer fenbendazole for his recovery.
- Fenbendazole, an anti-parasitic drug approved for veterinary use, is not FDA-approved for human cancer treatment.
- Some doctors, including oncologist Dr. William Makis, report success using protocols that include fenbendazole and ivermectin for various cancers.
- Patients like radio host Donna Leland claim to have recovered from cancer using these repurposed drugs, often in place of chemotherapy or radiation.
- Though unapproved, the protocol has gone viral globally, especially in China, under the name “Uncle Joey Protocol.”
The Rest of The Story:
Joe Tippens was told he had just three months to live after aggressive lung cancer spread throughout his body.
After trying standard treatments with no success, he began self-administering fenbendazole—typically used to deworm dogs—based on anecdotal success shared by a veterinarian.
Tippens combined the animal medication with supplements like Theracurmin and CBD. Within three months, he says he was cancer-free.
His story sparked international interest, and now thousands—including health professionals—are exploring the potential of anti-parasitic drugs in cancer therapy.
Physicians like Dr. William Makis are cautiously advocating their use, noting that the drugs disrupt cancer cells in multiple ways, from starving them of sugar to breaking down their internal scaffolding.
Still, the FDA maintains these drugs aren’t approved for human cancer treatment, citing the lack of clinical trials and safety data.
Commentary:
It shouldn’t take a death sentence to break free from the rigid orthodoxy of modern medicine. But that’s exactly what happened with Joe Tippens.
He was out of options, so he tried something off the beaten path—and it worked.
That’s what makes this story so compelling, and so frustrating.
A five-dollar animal dewormer may have done what hundreds of thousands of dollars in conventional cancer care couldn’t.
Yet instead of exploring it with urgency, the medical establishment is keeping it at arm’s length.
Why? Liability. Licensing boards. Big Pharma’s disinterest in cheap generics that don’t pad their bottom line.
Doctors who dare to think differently risk getting dragged through the mud or worse—losing their careers.
Meanwhile, patients are choosing to take matters into their own hands.
If the FDA won’t test these drugs for cancer, and the oncology industrial complex won’t touch them, who else but the patients will?
Critics may scoff that these drugs aren’t “proven.” But the burden of proof cuts both ways.
If we can pump kids full of mRNA on emergency-use authorizations, why is a decades-old worm pill for dogs treated like medical heresy?
Medical freedom isn’t just a slogan—it’s becoming a lifeline.
What Tippens and others are doing is what America used to be known for: innovation outside the system, driven by grit and necessity.
As more anecdotal reports roll in, there’s only one responsible path forward: real, rigorous trials.
Not to appease regulators—but to finally give desperate patients a fighting chance.
The Bottom Line:
The story of Joe Tippens challenges the cancer-care status quo and underscores the demand for medical freedom.
With growing patient interest and promising mechanisms, repurposed anti-parasitic drugs like fenbendazole deserve serious scientific scrutiny.
Ignoring them may cost lives.
Read Next
– UN Watchdog Destroys Dem Narrative Regarding Strike on Iran’s Nuclear Program
– Biden Appointed Federal Judge Orders Trump Admin to Release EV Funds to Blue States
